Michael Andrew Chambers - 18 Dec 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
19 Dec 2025, 16:40:45 UTC
Prior SEC filing
11 Mar 2025
Next SEC filing
05 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Andrew Chambers

Key filing fact

Michael Andrew Chambers filed Form 4 for Sarepta Therapeutics, Inc. (SRPT) on 19 Dec 2025.

Key facts

  • This page summarizes Michael Andrew Chambers's Form 4 filing for Sarepta Therapeutics, Inc. (SRPT).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 19 Dec 2025, 16:40.

Change

  • Previous filing in this sequence was filed on 11 Mar 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932527 Primary reporting owner

Chambers Michael Andrew

Relationship
Director
Address
215 FIRST STREET, SUITE 415, CAMBRIDGE
Signature
/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Andrew Chambers
Signature date
19 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRPT transaction Derivative

Convertible Senior Notes

Disposed to Issuer

Transaction value
$20,000,000
Shares
Change %
Price
Shares after
$0
Date
18 Dec 2025
Ownership
By Revocable Trust
Underlying class
Common Stock
Underlying amount
140,875
Exercise price
$141.97
Footnotes
F1, F2
SRPT transaction Derivative

Convertible Senior Notes

Award

Transaction value
$20,000,000
Shares
Change %
Price
Shares after
$20,000,000
Date
18 Dec 2025
Ownership
By Revocable Trust
Underlying class
Common Stock
Underlying amount
333,333
Exercise price
$60.00
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On December 10, 2025, the Reporting Person and the Company entered into an exchange agreement related to the exchange by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") for a combination of (i) $20,000,000 in aggregate principal amount of the Company's 4.875% Convertible Senior Notes due 2030 (the "2030 Notes") and (ii) $2,170,006.66 in cash in a private exchange with the Company. The exchange closed on December 18, 2025.

Footnote F2

The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

Footnote F3

The 2030 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 1, 2030, provided that certain convertibility conditions are met. On or after March 1, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date (August 29, 2030), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2030 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .